Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091695 · ClinicalTrials.gov registry record
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 100
- Enrollment target
NCT07091695: Completed study, sponsored by Bristol-Myers Squibb.
NCT07091695 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07091695 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the real-world use of neoadjuvant nivolumab+relatlimab or nivolumab+ipilimumab
Interventions
- BIOLOGICAL Nivolumab + ipilimumab
- BIOLOGICAL Nivolumab + relatlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-11 |
| Est. Completion | 2025-11-06 |
What the finished NCT07091695 record still lists
NCT07091695 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab + ipilimumab is the first listed.
NCT07091695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07091695 about?
NCT07091695 is a clinical study titled "Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab". The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the real-world use of neoadjuvant nivolumab+relatlimab or nivolumab+ipilim...
What is the current status of trial NCT07091695?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2025-05-11. Estimated completion is 2025-11-06.
What interventions are being tested in trial NCT07091695?
The interventions under investigation include: Nivolumab + ipilimumab (BIOLOGICAL), Nivolumab + relatlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT07091695?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI